Who’s Going to Festival of Biologics 2026

Oct 13–15, 2026 Basel, Switzerland ~3k attendees Website

378 companies and 389 speakers at Festival of Biologics 2026, a ~3,000-person, mostly industry meeting of biologics developers and manufacturers. As of Sep 26, 2026.

Showing 1–2 of 378 organizations

Organization	Festival of Biologics 2026 Attendance
Novartis Basel, Switzerland
novartis.com/about/manufacturing/contract-manufacturing Large pharmaGold sponsor Global pharmaceutical company whose contract manufacturing arm offers CDMO services for biologics, small molecules, cell and gene therapy, and fill-finish.	Booth Exhibiting at Booth 185 Keynote Tue Oct 13 09:10 Biotechnology, the Renaissance How advances in biology, AI and new treatment types are converging to change what medicine can do for patients. Chair Tue Oct 13 11:25 Chair's Remarks Clinical Trials Keynotes Chair Tue Oct 13 11:25 Chair's Remarks Antibody Keynotes Chair Tue Oct 13 11:25 Chair's Remarks Immunotherapy Keynotes Talk Tue Oct 13 11:30 Cell Line Development: Powering the Biotherapeutics Pipeline, Accelerating Patient Impact Bioprocessing Keynotes Panel Tue Oct 13 12:20 PANEL DISCUSSION: The Next Frontier: Delivering Next-Gen Science for Patients with High Unmet Need Immunotherapy Keynotes · with Memorial Sloan Kettering Cancer Center, STAb Therapeutics, Transgene +1 more Chair Tue Oct 13 14:05 Chair's Remarks Clinical Development & Operations Talk Tue Oct 13 14:50 Intensified Upstream Processing: Fed‑Batch and Perfusion Options for Robust Scale-Up Ways to get more protein from cell cultures by feeding them steadily or continuously, and how to scale that up reliably. Talk Tue Oct 13 15:10 AI for Immunogenicity Prediction of Biologics AI & Computational Approaches Panel Tue Oct 13 15:10 Panel Discussion: From Research to GMP: Making MSC Manufacturing Reproducible at Scale How to grow mesenchymal stromal cells, a kind of stem cell, the same way batch after batch as production scales up. with CSEM, HINA Bioventures, Corning Life Sciences Talk Tue Oct 13 15:30 Antibody x Conjugates: ADCs, AOCs and AxCs mAbs Chair Tue Oct 13 16:45 Chair's Remarks Protein Engineering Panel Tue Oct 13 17:30 Panel Discussion: Next Generation Antibody Formats Where antibody drug design is heading, from two-target antibodies and antibody-drug conjugates to AI's role in engineering them. with UCB, FairJourney Biologics, JJP Biologics Talk Tue Oct 13 17:30 What AI can do – or not – in Patient Engagement What AI can and cannot do when drug developers involve patients in research, and how to measure whether that involvement helps. Chair Wed Oct 14 11:25 Chair's Remarks Gene Therapy Chair Wed Oct 14 11:25 Chair's Remarks Downstream Processing Talk Wed Oct 14 11:30 The Good, the Bad and the Aggregated (Solving Protein Purification Mysteries)? Downstream Processing Talk Wed Oct 14 12:10 Introducing PAT into control strategies CMC & Developability Talk Wed Oct 14 12:30 Bovine AAV – a promising vector for pulmonary gene therapy Early results from using a cattle adeno-associated virus to deliver gene therapy to the lungs, including how immune systems recognise it. Talk Wed Oct 14 12:30 Title TBA AI & Computational Approaches Chair Wed Oct 14 14:05 Chair's Remarks AI & Computational Approaches Talk Wed Oct 14 14:30 Commercial Considerations for CAR-T Therapy: Lessons Learned from Recent Blockbusters What makes CAR-T cancer therapies hard to sell worldwide, from complex manufacturing and shipping to getting treatment centres and payers ready. Talk Wed Oct 14 15:30 When the Target Moves: Building Robust DSP Through Science, Monitoring, and Learning Why purification steps that once worked can start failing when the material feeding them changes, and how monitoring catches that early. Chair Wed Oct 14 16:45 Chair's Remarks Disease Areas: Neurodegenerative & CNS Chair Wed Oct 14 16:45 Chair's Remarks Regulated Bioanalysis Talk Wed Oct 14 16:50 The pivotal role of regulated bioanalysis in biotherapeutics development and approval Regulated Bioanalysis Talk Wed Oct 14 17:30 Protein Quality as a Critical Factor in Target Interference Assessment for Bioanalytical Assays How the quality of a lab-made protein can distort tests that check whether patients make antibodies against a biologic drug. Talk Wed Oct 14 17:50 An Oligonucleotide Program in Late-Stage Clinical Trials Lessons from keeping an anti-drug antibody test working for a cholesterol-lowering siRNA drug through late trials and a handover to a partner lab. Keynote Thu Oct 15 09:05 From Strategy to Delivery: Aligning Bioanalytical Innovation and Execution Across Clinical Phases How to decide what to measure, when and why, as biologic drugs move from early studies into late-stage clinical trials. Talk Thu Oct 15 09:40 Scaling the Future of Cell & Gene Therapies: From Scientific Innovation to Sustainable Platforms Manufacturing Chair Thu Oct 15 11:15 Chair's Remarks Fill/Finish Chair Thu Oct 15 11:15 Chair's Remarks Immunogenicity
Roche Basel, Switzerland
roche.com Large pharma Swiss pharmaceutical and diagnostics company with a large biologics portfolio.	Chair Tue Oct 13 14:05 Chair's Remarks Regulation Talk Tue Oct 13 14:10 Accelerating evidence generation with collaborative research Clinical Development & Operations Talk Tue Oct 13 14:30 Novel Orthogonal Receptor Platform Activating the IL12 Pathway in CAR-T Cells Using a Small-Molecule Ligand An engineered receptor that lets a small molecule switch on interleukin-12 signalling in CAR-T cells, improving tumour killing in animal models. Talk Tue Oct 13 15:10 Drug Product Development for Gene Therapies Formulation Chair Tue Oct 13 16:45 Chair's Remarks Clinical Development & Operations Talk Tue Oct 13 17:50 Data privacy and management for trials Clinical Development & Operations Chair Wed Oct 14 11:25 Chair's Remarks AI & Computational Approaches Talk Wed Oct 14 11:30 Strategy for potency determination of gene therapy products illustrated by rAAV Ways to measure whether a gene therapy made from adeno-associated virus actually works, and when an infectivity test can be skipped. Talk Wed Oct 14 14:30 Regulatory Reliance as a Catalyst for Biologics Access in Emerging Markets How regulators in emerging markets can lean on reviews already done by established agencies so patients get biologic drugs sooner. Talk Wed Oct 14 14:50 Drug Discovery in the Era of AI AI & Computational Approaches Talk Wed Oct 14 17:50 Biomarker potential of circulating methylated cfDNA signatures Precision Medicine & Biomarkers Chair Thu Oct 15 11:15 Chair's Remarks Proteomics & Mass Spectrometry Talk Thu Oct 15 11:20 Antibody bioconjugate analytics – Mass Spectrometry as a powerful tool for characterization Analytics & Screening Talk Thu Oct 15 12:00 Emerging Immunogenicity Challenges for Next-Generation Biotherapeutics Why newer antibody drugs can trigger unwanted immune reactions that sequence checks miss, and what laboratory and animal data reveal about the causes. Talk Thu Oct 15 12:20 Moving away from Acetonitrile and TFA to greener eluents in Biopharma LC-MS Proteomics & Mass Spectrometry Talk Thu Oct 15 12:40 A holistic approach to patient engagement: molecular development, devices and AI for the patient experience Patient Engagement and Study Activation

Instantly find 20 buyers from companies at Festival of Biologics 2026

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

What conference is this?

The Festival of Biologics Basel is Terrapinn’s annual European biologics meeting, held October 13–15, 2026 at Messe Basel. It brings together discovery, development, manufacturing, clinical and regulatory teams from pharma and biotech with the CDMOs, bioprocess, reagent and analytics suppliers that serve them, across tracks on protein engineering, AI, bispecifics, ADCs, immunotherapy, cell and gene therapy, vaccines, upstream and downstream processing, CMC, clinical development and market access.

What is in this guide?

Every organization we can place at Festival of Biologics 2026: 389 speakers from the public program (358 sessions) rolled up to their companies and institutions, plus the 188 sponsors and exhibitors from the public listing and floor plan with their stand numbers where published — 378 organizations in one list. Speakers appear as job titles, never by name.

How are organizations typed?

By the role an organization plays in biologics development: drug developers (large pharma and biotech), then the companies around them — CDMOs and CROs, bioprocess equipment and consumables, reagents and discovery tools, instruments and analytics, software and AI, consulting and other services — and academic, government and non-profit bodies. The topic filters come from the track a session sits in, and for keynotes and roundtables from the session’s own title and abstract.

How current is it?

Pulled from the public agenda, speaker list, sponsor and exhibitor listing and floor plan on September 26, 2026. Stand numbers come from the organizer’s floor plan; the exhibition’s opening hours are not published.

Organizations with their own page

261 organizations — every exhibitor and every organization with 2 or more presentations.

Not affiliated with or endorsed by Terrapinn or the Festival of Biologics. Submit a correction